Preliminary evidence on the safety profile of BNT162b2 (Comirnaty): new insights from data analysis in EudraVigilance and adverse reaction reports from an Italian health facility

The first vaccine against SARS-CoV-2 made available in Italy has been BNT162b2, the two-dose mRNA-based vaccine developed by Pfizer-BioNTech. The ASST Fatebenefratelli-Sacco hospital is located in one of the areas most affected by the pandemic, and to date over 2000 healthcare professionals have bee...

Descripción completa

Detalles Bibliográficos
Autores principales: Gringeri, Michele, Mosini, Giulia, Battini, Vera, Cammarata, Gianluca, Guarnieri, Greta, Carnovale, Carla, Clementi, Emilio, Radice, Sonia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Letters
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8171003/
https://www.ncbi.nlm.nih.gov/pubmed/34043934
http://dx.doi.org/10.1080/21645515.2021.1917236

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8171003/
https://www.ncbi.nlm.nih.gov/pubmed/34043934
http://dx.doi.org/10.1080/21645515.2021.1917236

Ejemplares similares